Researchers explore the rates of readmission over the first year among children who survived acute respiratory distress syndrome.
Three Trials Examine Dupilumab in Moderate-to-Severe Asthma
Three abstracts evaluating dupilumab (Dupixent) for moderate-to-severe asthma were presented at the recent American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting: VESTIGE, a